TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or dec...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Bejar, Rafael, Lord, Allegra, Stevenson, Kristen, Bar-Natan, Michal, Pérez-Ladaga, Albert, Zaneveld, Jacques, Wang, Hui, Caughey, Bennett, Stojanov, Petar, Getz, Gad, Garcia-Manero, Guillermo, Kantarjian, Hagop, Chen, Rui, Stone, Richard M., Neuberg, Donna, Steensma, David P., Ebert, Benjamin L.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2014
Fag:
Myeloid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208285/
https://ncbi.nlm.nih.gov/pubmed/25224413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-582809
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker